Logo

MD

Pediatrix Medical Group, Inc.

MD

Pediatrix Medical Group, Inc. • NYSE
$24.09 ▼ -1.47% (-0.36)
Market Cap $2.07 B
52w High $24.99
52w Low $11.84
Dividend Yield 0%
P/E 12.61
Volume 837.35K
Outstanding Shares 85.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $492.875M ▲ $72.298M ▲ $71.708M ▲ 14.549% ▲ $0.85 ▲ $96.387M ▲
Q2-2025 $468.844M ▲ $64.861M ▼ $39.26M ▲ 8.374% ▲ $0.45 ▲ $69.412M ▲
Q1-2025 $458.359M ▼ $70.541M ▼ $20.737M ▼ 4.524% ▼ $0.24 ▼ $42.576M ▼
Q4-2024 $502.364M ▼ $89.235M ▲ $30.48M ▲ 6.067% ▲ $0.35 ▲ $49.911M ▲
Q3-2024 $511.158M $82.994M $19.441M 3.803% $0.23 $41.615M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $463.101M ▲ $2.199B ▲ $1.309B ▲ $890.666M ▲
Q2-2025 $348.326M ▲ $2.102B ▲ $1.268B ▲ $833.753M ▲
Q1-2025 $219.176M ▼ $1.993B ▼ $1.204B ▼ $789.188M ▲
Q4-2024 $348.506M ▲ $2.153B ▲ $1.388B ▲ $764.938M ▲
Q3-2024 $220.452M $2.077B $1.344B $732.492M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $71.708M ▲ $137.285M ▲ $6.604M ▲ $-28.562M ▼ $115.327M ▼ $131.947M ▼
Q2-2025 $39.26M ▲ $137.167M ▲ $-7.154M ▲ $-4.259M ▲ $125.754M ▲ $132.652M ▲
Q1-2025 $20.737M ▼ $-117.463M ▼ $-7.464M ▼ $-6.035M ▼ $-130.962M ▼ $-120.781M ▼
Q4-2024 $30.48M ▲ $133.01M ▲ $-1.938M ▲ $-4.963M ▼ $126.109M ▲ $129.57M ▲
Q3-2024 $19.441M $91.838M $-4.338M $-3.071M $84.429M $85.548M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Health Care Patient Service
Health Care Patient Service
 $430.00M ▲$390.00M ▼$400.00M ▲$420.00M ▲
Hospitals Contracts
Hospitals Contracts
 $70.00M ▲$70.00M ▲$70.00M ▲$70.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has inched up over the past several years, showing that demand for Pediatrix’s services is holding up in its core women’s and children’s care markets. The concern is on profitability: operating income has moved from clearly positive to slightly negative, and net results have slipped from profits in the middle of the period back into losses recently. That pattern suggests rising costs, pricing pressure, or both, eroding margins even while the top line is stable to slightly higher. In short, the business is still busy, but it is currently not converting that activity into consistent earnings.

Balance Sheet

Balance Sheet The balance sheet shows a company that has deliberately slimmed down. Total assets have declined, but so has debt, meaning leverage has been reduced over time and financial risk from borrowing appears lower than a few years ago. Cash levels, which once were very high, dropped sharply and have only partially recovered, so the liquidity cushion is now more modest. Shareholders’ equity has softened from its peak, reflecting recent losses and possibly other adjustments. Overall, the company looks less debt-heavy than before, but it also has a smaller asset base and less spare cash to fall back on.

Cash Flow

Cash Flow Despite the recent accounting losses, the business continues to generate positive cash from its day‑to‑day operations, and free cash flow has stayed positive throughout the period. Capital spending needs are relatively low, which fits the profile of a physician‑services and technology‑enabled care model rather than a capital‑intensive hospital owner. This means Pediatrix can support its operations and some debt reduction or reinvestment from internal cash, even when reported profits are under pressure. The key watch point is whether this healthy cash generation can be sustained if margins remain thin or labor costs rise further.

Competitive Edge

Competitive Edge Pediatrix operates in a narrow but important niche: specialized care for newborns, high‑risk pregnancies, and pediatric subspecialties. Its scale and national network, especially in neonatal intensive care, give it a depth of experience and data that local competitors and small groups typically cannot match. Long‑standing, embedded relationships with hospitals create switching costs, because replacing Pediatrix’s teams and systems would be disruptive and risky for those facilities. At the same time, the company is exposed to broader industry pressures such as hospital consolidation, reimbursement changes, and competition from health systems that may try to bring these services in‑house. Its competitive position is strong in expertise and relationships, but it must keep demonstrating superior outcomes and value to maintain that edge.

Innovation and R&D

Innovation and R&D Innovation at Pediatrix is centered on clinical data, software, and new service models rather than traditional lab research. Its BabySteps Cloud system and large neonatal data warehouse give clinicians powerful tools for decision support, benchmarking, and quality improvement, which can translate into better outcomes and a differentiated service for hospitals. The organization also invests in research, education, and telehealth programs that extend its specialists into more locations and settings. Looking ahead, Pediatrix is pushing into areas like pediatric mental health and genomics, using partnerships and its own “Genomics Suite” to move toward more personalized care. These initiatives offer meaningful upside if they scale well, but they also carry execution risk and will take time before their financial impact is fully clear.

Summary

Pediatrix is a specialized healthcare services company with steady demand and a well‑defined niche in women’s and children’s care, supported by strong clinical data assets and long‑term hospital relationships. Financially, revenue has been resilient, but profitability has weakened in recent years, which is the central issue to monitor. The balance sheet has improved in terms of lower debt, but cash reserves are now more limited, leaving less room for prolonged weakness. Cash generation from operations remains a bright spot, helping to support ongoing innovation and strategic shifts. The company’s future trajectory will largely depend on its ability to restore margins, manage labor and reimbursement pressures, and successfully grow newer initiatives in telehealth, pediatric mental health, and genomics while preserving its core hospital-based franchise.

NEWS

November 3, 2025 · 6:00 AM UTC

Pediatrix Medical Group Reports Third Quarter Results

Read more

October 21, 2025 · 6:45 AM UTC

Pediatrix Medical Group 2025 Third Quarter Conference Call/Webcast Scheduled for Monday, November 3, 2025

Read more